Objective:To investigate therapeutic effect of rivaroxaban combined with indobufen on patients with atri-al fibrillation(AF)and coronary heart disease(CHD).Methods:This randomized controlled study enrolled 92 AF+CHD patients admitted in Wuxi Huishan District People's Hospital between August 2021 and July 2022.They were divided into control group(n=46,warfarin combined aspirin therapy)and intervention group(n=46,rivaroxaban combined indobufen therapy).After 3-month treatment,therapeutic effect,coagulant function,vascular endothe-lial function indexes,incidence of adverse events and adverse reactions during treatment were compared between two groups.Results:The total effective rate in intervention group was significantly higher than that of control group(93.48％vs.78.26％,P=0.036).Compared with patients in control group after treatment group,those in inter-vention group had significant higher thrombin time(TT)[(30.80±7.56)s vs.(36.24±8.63)s],activated partial thromboplastin time(APTT)[(37.13±6.57)s vs.(40.85±6.92)s],vascular endothelial growth factor(VEGF)[(467.56±69.42)ng/L vs.(519.15±73.46)ng/L],and significant lower platelet count(PLT)[(167.94±31.61)×109/L vs.(133.58±29.63)x 109/L],fibrinogen(Fg)[(3.43±0.77)g/L vs.(3.02±0.69)g/L],von Wille-brand factor(vWF)[(135.38±26.58)％vs.(119.87±22.19)％],angiotensin Ⅱ(Ang n)[(76.81±16.19)ng/L vs.(67.43±14.33)ng/L]and endothelin-1(ET-1)[(68.81±9.05)pg/L vs.(60.37±8.48)pg/L](P＜0.05 or＜0.01).Incidence of adverse events(8.70％vs.23.91％)and adverse reactions(8.70％vs.26.09％)in intervention group were significantly lower than those of control group(P＜0.05 both).Conclusion:Compared with warfarin combined with aspirin,rivaroxaban combined with indobufen can more effectively improve coagulant function and vascular endothelial function,improve the therapeutic effect and reduce the incidence of adverse events in patients with atrial fibrillation and coronary heart disease.
万方数据
维普
